- Home
- / SkinBioTherapeutics
SkinBioTherapeutics
Stock Price
£0.2
2024-10-29
Market Capitalization
£40.5 M
2024-10-29
Revenue
£4.6 M
FY, 2025
SkinBioTherapeutics Summary
Company Summary
- Overview
- SkinBioTherapeutics is a life science company focused on skin health. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Macclesfield, GB | view all locations
- Cybersecurity rating
Table of Contents
Key People
Martin Hunt, Non-Executive Chairman
Doug Quinn, Chief Financial Officer
Catherine Prescott, Non-Executive Director
LocationsView all
1 location detected
Macclesfield, England HQ
United Kingdom
Silk House
SkinBioTherapeutics Financials
Summary Financials
- Revenue (FY, 2025)
- £4.6M
- Gross profit (FY, 2025)
- £2.9M
- Net income (FY, 2025)
- (£696.0K)
- Cash (FY, 2025)
- £4.8M
- EBIT (FY, 2025)
- (£539.0K)
- Enterprise value
- $36.8M